NCT01938430View on ClinicalTrials.gov

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

PHASE2CompletedINTERVENTIONAL

Enrollment

339

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

March 31, 2015

Conditions

Chronic HCV Infection

Interventions

DRUG

LDV/SOF

LDV/SOF FDC tablet administered orally once daily

DRUG

RBV

RBV tablets administered orally in a divided daily dose

Trial Locations (30)

10016

New York

10032

New York

15213

Pittsburgh

19104

Philadelphia

20007

Washington D.C.

21093

Lutherville

23219

Richmond

27599

Chapel Hill

27710

Durham

32224

Jacksonville

33136

Miami

44195

Cleveland

46202

Indianapolis

48109

Ann Arbor

48202

Detroit

55455

Minneapolis

55905

Rochester

60611

Chicago

63110

St Louis

66160

Kansas City

75246

Dallas

80045

Aurora

84107

Murray

85054

Phoenix

92103

San Diego

94143

San Francisco

97239

Portland

98101

Seattle

98104

Seattle

02215

Boston

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY